{
  "links": "https://www.ycombinator.com/companies/arpeggio-bio",
  "name": "Arpeggio Bio",
  "headline": "Arpeggio Bio develops drugs targeting transcription factors using AIâ¦",
  "batch": "S19",
  "description": "Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted \"undruggable\" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.",
  "activity_status": "Active",
  "website": "http://www.arpeggiobio.com",
  "founded_date": 2018.0,
  "team_size": 20.0,
  "location": "Boulder, CO",
  "group_partner": null,
  "group_partner_yc": null,
  "company_linkedin": null,
  "company_twitter": null,
  "tags": "industry:biotech; industry:genomics; industry:drug-discovery",
  "founders": [],
  "status": true,
  "markdown": "raw_markdown=\"[![](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/65f4137d8d8a7ab6fa5c63a3_arp-logo-new.svg)](http://www.arpeggiobio.com/</>)\\n[Pipeline](http://www.arpeggiobio.com/</pipeline>)\\n[Technology](http://www.arpeggiobio.com/</technology>)\\n[About Us](http://www.arpeggiobio.com/</about-us>)\\n[Team](http://www.arpeggiobio.com/</about-us#team>)[Advisors](http://www.arpeggiobio.com/</about-us#advisors>)[Investors](http://www.arpeggiobio.com/</about-us#investors>)\\n[News/Blog](http://www.arpeggiobio.com/</news?category=News>)\\n[News](http://www.arpeggiobio.com/</news?category=News>)[Blogs](http://www.arpeggiobio.com/</news?category=Blog>)[What we're reading](http://www.arpeggiobio.com/</news?category=what+we%27re+reading>)\\n[Button](http://www.arpeggiobio.com/<#>)[Button](http://www.arpeggiobio.com/<#>)\\n[Careers](http://www.arpeggiobio.com/</careers>)\\n[Contact](http://www.arpeggiobio.com/</contact>)\\n![](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/6579abf05218ee8e2a5d28b1_main-nav-bottom.svg)![](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/6579abf0453ade864dbedb7b_main-top-mobile-nav.svg)\\n![](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/658c25e848c2232a04d5b855_mobile-bg-home.svg)\\n# \\nNetwork\\nbiology\\nmeets\\ndrug\\ndiscovery\\nWe engineer medicine based not on a single target, but the biological network as a whole.\\n+250k\\nChemotranscriptomesGenerated\\n+2.3B\\nmRNAs Measured\\n2\\nDrug Programs in the Pipeline\\n[View Pipeline](http://www.arpeggiobio.com/</pipeline>)[View Technology](http://www.arpeggiobio.com/</technology>)\\n![](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/6560d5092a6417fc8f93b262_hero-pattern.svg)\\n![](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/65f06e9a9238dcea99a55818_GettyImages-605765911.webp)\\n![Arpeggio Logo](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/656092ed08a5781a21fc326c_logo.svg)\\n![Arpeggio Logo](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/656092ed08a5781a21fc326c_logo.svg)\\n![Arpeggio Logo](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/656092ed08a5781a21fc326c_logo.svg)\\n![Arpeggio Logo](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/656092ed08a5781a21fc326c_logo.svg)\\n![Arpeggio Logo](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/656092ed08a5781a21fc326c_logo.svg)\\nOur Technology\\n## \\nChemo\\ntranscriptomes\\nArpeggio is developing the world's fastest platform for transcriptomic sequencing to learn how chemistry maps to network biology.\\n[Learn more about our technology](http://www.arpeggiobio.com/</technology>)\\n![](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/65f06e9a9031452e77417270_GettyImages-1031213660.webp)\\nOur Pipeline\\n## \\nChronic\\ndisease\\n99.5% of adults over fifty will have a chronic disease by 2040. We're working on developing a pipeline of potential drugs to tackle drug resistance in cancer, chronic kidney disease, and neurodegeneration.\\n[View our pipeline](http://www.arpeggiobio.com/</pipeline>)\\n## \\nFeatured\\nnews\\n[![](https://cdn.prod.website-files.com/65676b562936399ca62cfaa0/66171197a7b75b76580432ea_GettyImages-1244990743.jpg)News• May 29, 2024Kevin Eastwood Joins as Chief Business OfficerArpeggio is excited to announce Kevin Eastwood joining as CBO, bringing more than 25 years of experience at innovative pharmaceutical and therapeutics companies across the nation.](http://www.arpeggiobio.com/</news/kevin-eastwood-joins-arpeggio-as-chief-business-officer>)[![](https://cdn.prod.website-files.com/65676b562936399ca62cfaa0/66171197a7b75b76580432ea_GettyImages-1244990743.jpg)Kevin Eastwood Joins as Chief Business OfficerNewsNews• May 2024Arpeggio is excited to announce Kevin Eastwood joining as CBO, bringing more than 25 years of experience at innovative pharmaceutical and therapeutics companies across the nation.](http://www.arpeggiobio.com/<https:/www.slonepartners.com/kevin-eastwood-chief-business-officer-arpeggio-biosciences/>)\\n[![](https://cdn.prod.website-files.com/65676b562936399ca62cfaa0/6604437bc9499d1cae8acc5d_news-image-3.webp)News• September 7, 2022Arpeggio Raises $17M in Series AWe have partnered with Builders VC, and many returning investors, to develop our pipeline of transcriptomic medicine.](http://www.arpeggiobio.com/</news/newslink11>)[![](https://cdn.prod.website-files.com/65676b562936399ca62cfaa0/6604437bc9499d1cae8acc5d_news-image-3.webp)Arpeggio Raises $17M in Series ANewsNews• September 2022We have partnered with Builders VC, and many returning investors, to develop our pipeline of transcriptomic medicine.](http://www.arpeggiobio.com/<https:/www.businesswire.com/news/home/20220907005277/en/Arpeggio-Biosciences-Raises-17-Million-in-Series-A-Funding-Led-by-Builders-VC>)\\n[![](https://cdn.prod.website-files.com/65676b562936399ca62cfaa0/65f9be4baf9d7147593d6bb0_65f4512d0a019f1d78dbab62_65f06e998d253a98a360e80f_GettyImages-1223493781.webp)News• April 8, 2024Arpeggio at AACR 2024Arpeggio presented an exciting poster announcing our NRF2 degrader leading to regression of aggressive adenocarcinoma tumors in vivo.](http://www.arpeggiobio.com/</news/aacr2024>)[![](https://cdn.prod.website-files.com/65676b562936399ca62cfaa0/65f9be4baf9d7147593d6bb0_65f4512d0a019f1d78dbab62_65f06e998d253a98a360e80f_GettyImages-1223493781.webp)Arpeggio at AACR 2024NewsNews• April 2024Arpeggio presented an exciting poster announcing our NRF2 degrader leading to regression of aggressive adenocarcinoma tumors in vivo.](http://www.arpeggiobio.com/<https:/cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/6617f0aeda9cdbb985a9af43_AACR%202024.pdf>)\\nCareers\\n## \\nFaucibus\\namet\\ntur\\npise.\\nLorem ipsum dolor sit amet consectetur faucibus ametes tur pise sed ridiculus mollis turpis iaculis in turpis pulvinar vitae fermen tum convallis amet ultrices aliquam at.\\n[View Careers page](http://www.arpeggiobio.com/</careers>)\\n![](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/65707d5d7beb1c6a9eb3b0df_bg-image.svg)![](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/65e1970c6dfc22487ddbc3b1_Image%202%201.png)\\nContact us\\n### \\nLorem\\nipsum\\ndolo\\nsit\\namet\\nconsecte.\\nLorem ipsum dolor sit amet con sectetur faucibus ametest tur pis e sed ridiculus mollis turpis iac ulis in turpis pulvinar vitae ferm en tum convallis amet ultrices desrasd.\\n[Contact Us](http://www.arpeggiobio.com/</contact>)\\n[![](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/65f4137d8d8a7ab6fa5c63a3_arp-logo-new.svg)](http://www.arpeggiobio.com/</>)\\nPages\\n[Pipeline](http://www.arpeggiobio.com/</pipeline>)[Technology](http://www.arpeggiobio.com/</technology>)[About Us](http://www.arpeggiobio.com/</about-us>)\\n[Team](http://www.arpeggiobio.com/</about-us#team>)[Advisors](http://www.arpeggiobio.com/</about-us#advisors>)[Investors](http://www.arpeggiobio.com/</about-us#investors>)\\n[News](http://www.arpeggiobio.com/</news?category=News>)[Blog](http://www.arpeggiobio.com/</news?category=Blog>)[Careers](http://www.arpeggiobio.com/</careers>)\\nContact\\ninfo@arpeggiobio.com\\n[](http://www.arpeggiobio.com/<https:/www.linkedin.com/company/arpeggio-biosciences/>)[](http://www.arpeggiobio.com/<https:/twitter.com/ArpeggioBio>)\\n\" markdown_with_citations=\"![⟨1⟩](http://www.arpeggiobio.com/</>)\\nPipeline⟨2⟩\\nTechnology⟨3⟩\\nAbout Us⟨4⟩\\nTeam⟨5⟩Advisors⟨6⟩Investors⟨7⟩\\nNews/Blog⟨8⟩\\nNews⟨8⟩Blogs⟨9⟩What we're reading⟨10⟩\\nButton⟨11⟩Button⟨11⟩\\nCareers⟨12⟩\\nContact⟨13⟩\\n![](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/6579abf05218ee8e2a5d28b1_main-nav-bottom.svg)![](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/6579abf0453ade864dbedb7b_main-top-mobile-nav.svg)\\n![](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/658c25e848c2232a04d5b855_mobile-bg-home.svg)\\n# \\nNetwork\\nbiology\\nmeets\\ndrug\\ndiscovery\\nWe engineer medicine based not on a single target, but the biological network as a whole.\\n+250k\\nChemotranscriptomesGenerated\\n+2.3B\\nmRNAs Measured\\n2\\nDrug Programs in the Pipeline\\nView Pipeline⟨2⟩View Technology⟨3⟩\\n![](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/6560d5092a6417fc8f93b262_hero-pattern.svg)\\n![](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/65f06e9a9238dcea99a55818_GettyImages-605765911.webp)\\n![Arpeggio Logo⟨14⟩]\\n![Arpeggio Logo⟨14⟩]\\n![Arpeggio Logo⟨14⟩]\\n![Arpeggio Logo⟨14⟩]\\n![Arpeggio Logo⟨14⟩]\\nOur Technology\\n## \\nChemo\\ntranscriptomes\\nArpeggio is developing the world's fastest platform for transcriptomic sequencing to learn how chemistry maps to network biology.\\nLearn more about our technology⟨3⟩\\n![](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/65f06e9a9031452e77417270_GettyImages-1031213660.webp)\\nOur Pipeline\\n## \\nChronic\\ndisease\\n99.5% of adults over fifty will have a chronic disease by 2040. We're working on developing a pipeline of potential drugs to tackle drug resistance in cancer, chronic kidney disease, and neurodegeneration.\\nView our pipeline⟨2⟩\\n## \\nFeatured\\nnews\\n![⟨15⟩News• May 29, 2024Kevin Eastwood Joins as Chief Business OfficerArpeggio is excited to announce Kevin Eastwood joining as CBO, bringing more than 25 years of experience at innovative pharmaceutical and therapeutics companies across the nation.](http://www.arpeggiobio.com/</news/kevin-eastwood-joins-arpeggio-as-chief-business-officer>)![⟨15⟩Kevin Eastwood Joins as Chief Business OfficerNewsNews• May 2024Arpeggio is excited to announce Kevin Eastwood joining as CBO, bringing more than 25 years of experience at innovative pharmaceutical and therapeutics companies across the nation.](http://www.arpeggiobio.com/<https:/www.slonepartners.com/kevin-eastwood-chief-business-officer-arpeggio-biosciences/>)\\n![⟨16⟩News• September 7, 2022Arpeggio Raises $17M in Series AWe have partnered with Builders VC, and many returning investors, to develop our pipeline of transcriptomic medicine.](http://www.arpeggiobio.com/</news/newslink11>)![⟨16⟩Arpeggio Raises $17M in Series ANewsNews• September 2022We have partnered with Builders VC, and many returning investors, to develop our pipeline of transcriptomic medicine.](http://www.arpeggiobio.com/<https:/www.businesswire.com/news/home/20220907005277/en/Arpeggio-Biosciences-Raises-17-Million-in-Series-A-Funding-Led-by-Builders-VC>)\\n![⟨17⟩News• April 8, 2024Arpeggio at AACR 2024Arpeggio presented an exciting poster announcing our NRF2 degrader leading to regression of aggressive adenocarcinoma tumors in vivo.](http://www.arpeggiobio.com/</news/aacr2024>)![⟨17⟩Arpeggio at AACR 2024NewsNews• April 2024Arpeggio presented an exciting poster announcing our NRF2 degrader leading to regression of aggressive adenocarcinoma tumors in vivo.](http://www.arpeggiobio.com/<https:/cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/6617f0aeda9cdbb985a9af43_AACR%202024.pdf>)\\nCareers\\n## \\nFaucibus\\namet\\ntur\\npise.\\nLorem ipsum dolor sit amet consectetur faucibus ametes tur pise sed ridiculus mollis turpis iaculis in turpis pulvinar vitae fermen tum convallis amet ultrices aliquam at.\\nView Careers page⟨12⟩\\n![](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/65707d5d7beb1c6a9eb3b0df_bg-image.svg)![](https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/65e1970c6dfc22487ddbc3b1_Image%202%201.png)\\nContact us\\n### \\nLorem\\nipsum\\ndolo\\nsit\\namet\\nconsecte.\\nLorem ipsum dolor sit amet con sectetur faucibus ametest tur pis e sed ridiculus mollis turpis iac ulis in turpis pulvinar vitae ferm en tum convallis amet ultrices desrasd.\\nContact Us⟨13⟩\\n![⟨1⟩](http://www.arpeggiobio.com/</>)\\nPages\\nPipeline⟨2⟩Technology⟨3⟩About Us⟨4⟩\\nTeam⟨5⟩Advisors⟨6⟩Investors⟨7⟩\\nNews⟨8⟩Blog⟨9⟩Careers⟨12⟩\\nContact\\ninfo@arpeggiobio.com\\n[](http://www.arpeggiobio.com/<https:/www.linkedin.com/company/arpeggio-biosciences/>)[](http://www.arpeggiobio.com/<https:/twitter.com/ArpeggioBio>)\\n\" references_markdown=\"\\n\\n## References\\n\\n⟨1⟩ https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/65f4137d8d8a7ab6fa5c63a3_arp-logo-new.svg: ![\\n⟨2⟩ http://www.arpeggiobio.com/</pipeline>: Pipeline\\n⟨3⟩ http://www.arpeggiobio.com/</technology>: Technology\\n⟨4⟩ http://www.arpeggiobio.com/</about-us>: About Us\\n⟨5⟩ http://www.arpeggiobio.com/</about-us#team>: Team\\n⟨6⟩ http://www.arpeggiobio.com/</about-us#advisors>: Advisors\\n⟨7⟩ http://www.arpeggiobio.com/</about-us#investors>: Investors\\n⟨8⟩ http://www.arpeggiobio.com/</news?category=News>: News/Blog\\n⟨9⟩ http://www.arpeggiobio.com/</news?category=Blog>: Blogs\\n⟨10⟩ http://www.arpeggiobio.com/</news?category=what+we%27re+reading>: What we're reading\\n⟨11⟩ http://www.arpeggiobio.com/<#>: Button\\n⟨12⟩ http://www.arpeggiobio.com/</careers>: Careers\\n⟨13⟩ http://www.arpeggiobio.com/</contact>: Contact\\n⟨14⟩ https://cdn.prod.website-files.com/65608c8c206ee41e5ab7e0e9/656092ed08a5781a21fc326c_logo.svg: Arpeggio Logo\\n⟨15⟩ https://cdn.prod.website-files.com/65676b562936399ca62cfaa0/66171197a7b75b76580432ea_GettyImages-1244990743.jpg: ![\\n⟨16⟩ https://cdn.prod.website-files.com/65676b562936399ca62cfaa0/6604437bc9499d1cae8acc5d_news-image-3.webp: ![\\n⟨17⟩ https://cdn.prod.website-files.com/65676b562936399ca62cfaa0/65f9be4baf9d7147593d6bb0_65f4512d0a019f1d78dbab62_65f06e998d253a98a360e80f_GettyImages-1223493781.webp: ![\\n\" fit_markdown='' fit_html=''",
  "generated_description": "**Arpeggio Bio** is a cutting-edge biotech company that combines artificial intelligence with high-throughput RNA sequencing to take on the challenging world of *transcription factors* in drug development. Founded in 2018 and based in Boulder, Colorado, Arpeggio is part of Y Combinator's Batch S19 and has successfully raised $20 million in venture capital to further its mission.\n\nAt the core of what Arpeggio Bio does is their innovative platform targeting \"undruggable\" proteins such as NRF2, TEAD, and GPX4. Their lead program is currently racing towards a Development Candidate (DC) aimed at treating immune-oncology resistant melanoma—a testament to their ambition in the fiercely competitive pharmaceutical landscape.\n\nThe team, comprised of about 20 talented individuals, has established notable collaborations with prestigious companies like Johnson & Johnson and FORMA, demonstrating early validation of their platform's efficacy in fields like rare disease and inflammation. With promising results from a significant Phase I clinical trial, the future looks optimistic.\n\nArpeggio's vision goes beyond just single-target drugs; they’re designing medicines that consider the biological network as a whole. They’ve already generated over 250,000 chemotranscriptomes and measured more than 2.3 billion mRNAs, positioning themselves as leaders in transcriptomic research.\n\nCurrently, Arpeggio is pioneering solutions to combat drug resistance in chronic diseases, including cancer and neurodegeneration. With two drug programs in their pipeline, they aim to tackle issues that affect a substantial portion of the adult population, especially as chronic diseases are projected to impact nearly all adults over fifty by 2040.\n\nIn the ever-evolving landscape of biotech, Arpeggio Bio stands out as a unique player, merging advanced technology with a commitment to innovate in drug discovery. For more details, you can explore their website at [Arpeggio Bio](http://www.arpeggiobio.com).\n\n### Summary\n- **Founded**: 2018\n- **Location**: Boulder, CO\n- **Funding**: $20M in venture capital\n- **Team**: 20 employees\n- **Key Partnerships**: Johnson & Johnson, FORMA\n- **Focus**: \"Undruggable\" proteins and AI-driven drug development\n- **Pipeline**: Drugs for chronic diseases, including cancer\n- **Website**: [www.arpeggiobio.com](http://www.arpeggiobio.com)"
}